We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 18, 2022

Switch to Fulvestrant and Palbociclib vs No Switch in Advanced Breast Cancer With Rising ESR1 Mutations During Aromatase Inhibitor and Palbociclib Therapy

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
Lancet Oncol 2022 Sep 29;[EPub Ahead of Print], FC Bidard, AC Hardy-Bessard, F Dalenc, T Bachelot, JY Pierga, T de la Motte Rouge, R Sabatier, C Dubot, JS Frenel, JM Ferrero, S Ladoire, C Levy, MA Mouret-Reynier, A Lortholary, J Grenier, C Chakiba, L Stefani, JE Plaza, F Clatot, L Teixeira, V D'Hondt, H Vegas, O Derbel, C Garnier-Tixidre, JL Canon, B Pistilli, F André, L Arnould, A Pradines, I Bièche, C Callens, J Lemonnier, F Berger, S Delaloge

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading